Miami, FL: A newly formulated version of Marinol (synthetic THC) that may be administered via an inhaler rather than orally will be tested as a treatment for severe migraine headaches, Solvay Pharmaceuticals announced at last week’s American Academy of Neurology (AAN) Annual Meeting in Miami.
Marinol, an FDA-approved Schedule III drug, is consumed orally in pill form by patients suffering from HIV/AIDS and/or undergoing chemotherapy. However, Marinol’s therapeutic effects may be delayed by as much as 1-2 hours following consumption because the drug is slowly metabolized by the liver, which converts it into various highly psychoactive chemical compounds.
In a recent clinical trial, patients administered a new formulation of Marinol by a pressurized metered dose inhaler gained rapid systemic absorption from the drug. Solvay intends to test the efficacy, safety, and tolerability of inhaled Marinol for migraine in a placebo-controlled trial later this year, the company announced.
“Pulmonary Dronabinol (Marinol) has potential application in a variety of conditions, such as the treatment of migraines, nausea, pain management and spasticity … and could offer an alternative for patients when a fast onset of action is desirable,” the company said in a press release.
For more information, please contact Paul Armentano, NORML Senior Policy Analyst, at (202) 483-5500.